Alzheimer s & Dementia · 2018 · 162 citations · 36 references
MedicineNeurologyNeuroscienceCognitive NeuroscienceDementiaNeurodegenerationCognitive ImpairmentDementia BiomarkersDemyelinating DisordersMagnetic Resonance ImagingNeurodegenerative DiseasesVascular DementiaMagnetic ResonanceMagnetic Resonance Relaxation TimesMagnetization Transfer ImagingMild Cognitive Impairment ImagingMyelination ImpairmentQuantitative Magnetic Resonance ImagingWhite Matter AgingWhite Matter Integrity
INTRODUCTION: We investigated brain demyelination in aging, mild cognitive impairment (MCI), and dementia using a direct magnetic resonance imaging marker of myelin. METHODS: Brains of young and old controls, and old subjects with MCI, Alzheimer's disease, or vascular dementia were scanned using our recently developed myelin water fraction (MWF) mapping technique, which provides greatly improved accuracy over previous comparable methods. Maps of MWF, a direct and specific myelin measure, and relaxation times and magnetization transfer ratio, indirect and nonspecific measures, were constructed. RESULTS: MCI subjects showed decreased MWF compared with old controls. Demyelination was greater in Alzheimer's disease or vascular dementia. As expected, decreased MWF was accompanied by decreased magnetization transfer ratio and increased relaxation times. The young subjects showed greater myelin content than the old subjects. DISCUSSION: We believe this to be the first demonstration of myelin loss in MCI, Alzheimer's disease, and vascular dementia using a method that provides a quantitative magnetic resonance imaging-based measure of myelin. Our findings add to the emerging evidence that myelination may represent an important biomarker for the pathology of MCI and dementia. This study supports the investigation of the role of myelination in MCI and dementia through use of this quantitative magnetic resonance imaging approach in clinical studies of disease progression, and relationship of functional status to myelination status. Furthermore, mapping MWF may permit myelin to serve as a therapeutic target in clinical trials.
36
Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy
Maj-Linda B. Selenica, Milene L. Brownlow, Jeffy P. Jimenez et al. · Neurodegenerative Diseases · 2012 · 10.4K citations · Full text
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Dale Schenk, Robin Barbour, Whitney Dunn et al. · Nature · 1999 · 3.2K citations
Neurodegenerative Diseases Target Large-Scale Human Brain Networks
William W. Seeley, Richard K. Crawford, Juan Zhou et al. · Neuron · 2009 · 2.4K citations · Full text
Randy L. Buckner, Abraham Z. Snyder, Benjamin J. Shannon et al. · Journal of Neuroscience · 2005 · 2.1K citations · Full text
Mild Cognitive Impairment Represents Early-Stage Alzheimer Disease
Martha Storandt, J. Philip Miller, Daniel W. McKeel et al. · Archives of Neurology · 2001 · 1.9K citations